Details for Patent: 8,815,889

Which drugs does patent 8,815,889 protect, and when does it expire?

Patent 8,815,889 protects CONTRAVE and is included in one NDA.

This patent has twenty-seven patent family members in fourteen countries.

Summary for Patent: 8,815,889

Patent landscape, scope, and claims:

Title:	Compositions and methods for increasing insulin sensitivity
Abstract:	Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
Inventor(s):	Cowley; Michael A. (Portland, OR), McKinney; Anthony A. (San Diego, CA), Tollefson; Gary (Indianapolis, IN)
Assignee:	Orexigen Therapeutics, Inc. (San Diego, CA)
Application Number:	11/602,571
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,815,889
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,815,889

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes	8,815,889					FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE

International Family Members for US Patent 8,815,889

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	057631
Australia	2006323048
Brazil	PI0618918
Canada	2630624